SCHEMBL6740907

SCHEMBL6740907

CCc1oc2ccccc2c1C(=O)c1cc(C(C)C)c(OS(=O)(=O)c2ccc(C(=O)O)c(O)c2)c(C(C)C)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 9/20 0.53
CYP2C19 P33261 6/20 0.48
EYA3 Q99504 3/20 0.48
CYP2C9 P11712 3/20 0.48
MEN1 O00255 2/20 0.48
ABCB11 O95342 2/20 0.48
LMNA P02545 2/20 0.48
TTR P02766 2/20 0.48
PGR P06401 2/20 0.48
ADRA2A P08913 2/20 0.48
TBXA2R P21731 2/20 0.48
OPRM1 P35372 2/20 0.48
SLC6A3 Q01959 2/20 0.48
KMT2A Q03164 2/20 0.48
BIRC5 O15392 1/20 0.48
HTR1A P08908 1/20 0.48
DRD1 P21728 1/20 0.48
PTGS1 P23219 1/20 0.48
SLC6A2 P23975 1/20 0.48
PDE4A P27815 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6736009 0.89 PTPN1 (0.63) PTPN1CYP2C19EYA3CYP2C9MEN1
SCHEMBL7561828 0.88 PTPN1 (0.56) PTPN1CYP2C19EYA3CYP2C9MEN1
SCHEMBL6737244 0.88 CYP2C19 (0.61) PTPN1CYP2C19EYA3CYP2C9MEN1
SCHEMBL6736406 0.81 PTPN1 (0.49) PTPN1CYP2C19EYA3CYP2C9MEN1
SCHEMBL7564914 0.80 PTPN1 (0.53) PTPN1EYA3CYP2C9ABCB11TTR
SCHEMBL6735279 0.79 PTPN1 (0.52) PTPN1
SCHEMBL7962390 0.77 PTPN1 (0.46) PTPN1CYP2C19EYA3CYP2C9MEN1
SCHEMBL6739280 0.77 PTPN1 (0.59) PTPN1EYA3TTRNR1H4
SCHEMBL6737999 0.76 EYA3 (0.71) PTPN1CYP2C19EYA3CYP2C9MEN1
SCHEMBL6731794 0.76 PTPN1 (0.42) PTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030073709-A1 Furans, benzofurans, and thiophenes useful in the treatment of insulin resistance and hyperglycemia WYETH 2003-04-17 US claimed
US-20020035272-A1 Furans, benzofurans, and thiophenes useful in the treatment of insulin resistance and hyperglycemia AMERICAN HOME PRODUCTS CORPORATION 2002-03-21 US claimed
US-6103708-A USEFUL IN TREATING METABOLIC DISORDERS RELATED TO INSULIN RESISTANCE OR HYPERGLYCEMIA AMERICAN HOME PRODUCTS CORPORATION (US) 2000-08-15 US claimed
US-6683107-B2 THERAPY OF METABOLISM DISORDERS WYETH 2004-01-27 US disclosed
US-20030073709-A1 Furans, benzofurans, and thiophenes useful in the treatment of insulin resistance and hyperglycemia WYETH 2003-04-17 US disclosed
US-6451845-B1 ANTIDIABETIC AGENTS WYETH 2002-09-17 US disclosed
US-20020035272-A1 Furans, benzofurans, and thiophenes useful in the treatment of insulin resistance and hyperglycemia AMERICAN HOME PRODUCTS CORPORATION 2002-03-21 US disclosed
US-6248764-B1 ANTIDIABETIC AGENT; HYPOGLYCEMIC AGENT AMERICAN HOME PRODUCTS CORPORATION 2001-06-19 US disclosed
US-6103708-A USEFUL IN TREATING METABOLIC DISORDERS RELATED TO INSULIN RESISTANCE OR HYPERGLYCEMIA AMERICAN HOME PRODUCTS CORPORATION (US) 2000-08-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073709-A1 Furans, benzofurans, and thiophenes useful in the treatment of insulin resistance and hyperglycemia GPR119, INSR, FFAR3 PTPN1 178/4885CYP2C19 2141/4885EYA3 3536/4885
US-20020035272-A1 Furans, benzofurans, and thiophenes useful in the treatment of insulin resistance and hyperglycemia INSR, GPR119, FFAR3 PTPN1 200/4885CYP2C19 2160/4885EYA3 3483/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.